Survival after secondary cytoreductive surgery and chemotherapy compared with chemotherapy alone for first recurrence in patients with platinum-sensitive epithelial ovarian cancer and no residuals after primary treatment. A registry-based study.

Introduction: The aim of this study was to investigate whether secondary cytoreductive surgery and platinum-based chemotherapy improved survival among patients with recurrent, platinum-sensitive epithelial ovarian cancer compared with those who received platinum-based chemotherapy alone, and to identify possible predictors for selection to secondary cytoreductive surgery.

Material And Methods: We included 397 patients who had a primary diagnosis of FIGO stage I-IV epithelial ovarian cancer recorded in the Cancer Registry of Norway between 1 January 2002 and 31 December 2012, received primary surgery with no residuals followed by platinum-based chemotherapy, had first recurrence six or more months after completion of primary platinum-based chemotherapy, and received secondary treatment with either secondary cytoreductive surgery and platinum-based chemotherapy (secondary cytoreductive surgery+platinum-based chemotherapy group) or platinum-based chemotherapy alone (platinum-based chemotherapy group). Outcomes were progression-free survival to second recurrence or death and overall survival.

Pre-induction cervical ripening with 25 microg and 50 microg vaginal misoprostol in 181 nulliparous parturients.

Objective: To evaluate the effect of intravaginally misoprostol at start dosages of 25 microg and 50 microg when used for pre-induction cervical ripening among nulliparous parturients.

Methods: Our observational study involves all cases of partus induction consecutively registered in a Norwegian hospital between September 2002 and August 2006, with the following inclusion criteria: nulliparous, singleton pregnancies >or=37 weeks, an unfavourable cervix (Bishop score 2499 g, received misoprostol vaginally every 6 h upto four times. Seventy-six women started with 25 microg (25 microg-group) and 105 started with 50 microg (50 microg-group).

Bishop score and the outcome of labor induction with misoprostol.

Background: The aim of the study was to retrospectively identify possible factors for predicting the outcome of induction with misoprostol.

Methods: Fifty micrograms of misoprostol were administered intravaginally every 6 h during the first 2 days of induction, up to a maximum of 4 doses. The Bishop score, indication for induction, gestational length, maternal age, and parity were analyzed.